Thomas Lodise, PharmD, PhD

home / authors / thomas-lodise-pharmd-phd

Articles

Unmet Needs in Management of C. Difficile Infection (CDI)

Paul Feuerstadt, MD, FACG, AGAF;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

October 12th 2022

Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).

Differences between Fecal Microbiota Transplantation Studies to Treat C. difficile Infection (CDI)

Paul Feuerstadt, MD, FACG, AGAF;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

October 12th 2022

Experts discuss differences in designs of clinical trials of 4 emerging microbiota-based live biotherapeutics - RBX2660, SER-109, CP101, VE303, for treatment of rCDI.

RBX2660 for Treatment of Recurrent C. difficile Infection (rCDI)

Paul Feuerstadt, MD, FACG, AGAF;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

October 5th 2022

Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.

Published: October 23rd 2024 | Updated: October 24th 2024

What to Know About E Coli Outbreak Linked to McDonald’s Quarter Pounders